TY - JOUR
T1 - Ototoxicity monitoring in children treated with platinum chemotherapy
AU - Brooks, Beth
AU - Knight, Kristin
PY - 2017/7/21
Y1 - 2017/7/21
N2 - Objective: To review the prevalence, mechanisms, clinical presentation, risk factors and implications of platinum-induced ototoxicity in paediatric cancer patients based on published evidence, discuss options for monitoring hearing in young children during treatment and review long-term follow-up guidelines. Design: Narrative literature review. Results: Children treated with cisplatin are at high risk of hearing loss and early, accurate identification of ototoxicity is important for medical decision making and hearing rehabilitation. Challenges of monitoring hearing in young children during cancer treatment and options for monitoring hearing are discussed. Conclusion: Hearing loss has important consequences for the survivors of childhood cancer including communication, learning, cognition and quality of life. Due to the presentation and configuration of ototoxic hearing loss, the test frequencies that are prioritised and the sequence of testing may differ from standard paediatric hearing evaluations. Hearing should be monitored during treatment and after completion of therapy.
AB - Objective: To review the prevalence, mechanisms, clinical presentation, risk factors and implications of platinum-induced ototoxicity in paediatric cancer patients based on published evidence, discuss options for monitoring hearing in young children during treatment and review long-term follow-up guidelines. Design: Narrative literature review. Results: Children treated with cisplatin are at high risk of hearing loss and early, accurate identification of ototoxicity is important for medical decision making and hearing rehabilitation. Challenges of monitoring hearing in young children during cancer treatment and options for monitoring hearing are discussed. Conclusion: Hearing loss has important consequences for the survivors of childhood cancer including communication, learning, cognition and quality of life. Due to the presentation and configuration of ototoxic hearing loss, the test frequencies that are prioritised and the sequence of testing may differ from standard paediatric hearing evaluations. Hearing should be monitored during treatment and after completion of therapy.
UR - http://www.scopus.com/inward/record.url?scp=85025672196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025672196&partnerID=8YFLogxK
U2 - 10.1080/14992027.2017.1355570
DO - 10.1080/14992027.2017.1355570
M3 - Article
C2 - 28737048
AN - SCOPUS:85025672196
SP - 1
EP - 7
JO - International Journal of Audiology
JF - International Journal of Audiology
SN - 1499-2027
ER -